Olanzapine enhances the response of PD-(L)1 inhibitor immunotherapy: A retrospective efficacy analysis in advanced malignancies
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
This retrospective cohort study explores olanzapine's immunomodulatory role and clinical impact in patients with advanced cancer on PD-(L)1 inhibitors, given that chronic stress may impair immune checkpoint inhibitor (ICI) efficacy. Among 1933 patients with advanced cancer receiving PD-(L)1 inhibitors + chemotherapy (2018–2022), 99 received concurrent olanzapine for chemotherapy-induced nausea. After excluding 58 cases, 41 olanzapine-treated patients were propensity score-matched (PSM) for age, gender, and cancer type. Survival outcomes were analyzed via Kaplan-Meier curves and log rank tests. The olanzapine cohort showed higher objective response rate (ORR) (39.02% vs. 26.83%), comparable median PFS (9 vs. 6 months, p = 0.057), and significantly longer median OS (28 vs. 9 months, p = 0.019). Multivariate analysis confirmed olanzapine correlated with prolonged OS (HR = 0.510, 95% CI:0.282–0.917, p = 0.026). Olanzapine may enhance survival benefits in patients with advanced cancer undergoing PD-(L)1 inhibitor therapy.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Cancer
Stress
Anesthesia
and Immune Response
Immunotherapy and Immune Responses
Publication details
- Journal / source
- iScience
- Volume
- 29
- Issue
- 5
- Pages
- 115568–115568
- Publication date
- 2 April 2026
- Language
- EN